RENAL CELL CARCINOMA (RCC)

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding a safe dose, and then seeing if it shrinks tumors. About 7…

This study tests if a combination of three treatments—a targeted procedure to block blood flow to the tumor, an immunotherapy drug, and a targeted therapy pill—can shrink advanced kidney cancer before surgery. About 40 adults with certain stages of kidney cancer will receive this…

This study tests whether adding tivozanib to the standard immunotherapy pembrolizumab can better prevent high-risk kidney cancer from returning after surgery. About 1,040 adults with clear cell renal cell carcinoma at intermediate-high or high risk will be randomly assigned to ge…

This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…

This study tests whether PET/CT scans can safely guide a treatment break for people with advanced kidney cancer. Participants must have responded well to at least 12 months of standard therapy. The goal is to see if stopping treatment based on scan results can maintain disease co…

This early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…

This early-phase study tests a new drug called Sapu003 in 27 adults with advanced solid tumors (like breast, kidney, or liver cancer) that are sensitive to mTOR-targeted therapy. The main goal is to find the safest dose and check for side effects. Participants receive Sapu003 wee…

This early-phase study tests a new drug called CTX-10726 in people with advanced cancers (stomach, liver, uterine, or kidney) that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 70 adults will take part, and th…

This study is testing a new way to give radiation for kidney cancer that uses advanced imaging to target the tumor more precisely. The goal is to reduce radiation to the healthy part of the kidney, which may help preserve kidney function. About 40 adults with kidney cancer that h…

This study tests a new drug, 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell renal cell carcinoma that has come back or spread. The trial compares two different doses of the drug to standard single-drug therapy to …

This study looks at whether taking cabozantinib less often (skipping doses) works just as well as the usual way of lowering the dose for people with advanced kidney cancer. About 34 adults who are already on a stable dose will try both methods for 4 weeks each. Researchers will c…

This early-phase study tests a new experimental drug (LB-LR1109) in people with advanced solid tumors like lung, kidney, or skin cancer that no longer respond to standard treatments. The study has two parts: first, the drug is given alone to find the safest dose; second, it is co…

This study compares two ways to remove a kidney: laparoscopic (keyhole) surgery and open surgery. Researchers want to see which method leads to a shorter hospital stay, less blood loss, and lower costs. The study involves 60 adults who need kidney removal due to a non-working kid…

This study looks at immune cells in the lymph nodes of people with kidney cancer to learn how the body fights the disease. Researchers will analyze tissue samples from tumors and lymph nodes to understand cancer biology and treatment responses. About 10 adults with known or suspe…

This study looks back at medical records from 4,700 kidney cancer patients treated between 2012 and 2024. The goal is to create a tool that can predict how the disease will progress and help doctors choose the best treatment for each patient. No new drugs or treatments are being …